You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Takahiro Yamasaki + 1629 word(s) 1629 2021-02-26 04:53:19 |
2 format correct Vivi Li Meta information modification 1629 2021-03-10 08:36:36 | |
3 format correct Conner Chen Meta information modification 1629 2021-10-12 05:30:00 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Yamasaki, T. Hepatic Arterial Infusion Chemotherapy. Encyclopedia. Available online: https://encyclopedia.pub/entry/7897 (accessed on 06 December 2025).
Yamasaki T. Hepatic Arterial Infusion Chemotherapy. Encyclopedia. Available at: https://encyclopedia.pub/entry/7897. Accessed December 06, 2025.
Yamasaki, Takahiro. "Hepatic Arterial Infusion Chemotherapy" Encyclopedia, https://encyclopedia.pub/entry/7897 (accessed December 06, 2025).
Yamasaki, T. (2021, March 10). Hepatic Arterial Infusion Chemotherapy. In Encyclopedia. https://encyclopedia.pub/entry/7897
Yamasaki, Takahiro. "Hepatic Arterial Infusion Chemotherapy." Encyclopedia. Web. 10 March, 2021.
Hepatic Arterial Infusion Chemotherapy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/app11041882

HAIC involves two procedures as follows: as scheduled, chemotherapeutic regimens are administered through a reservoir port connected to a catheter, which is implanted under the skin, and a catheter is inserted each time without implantation of the reservoir port. As HAIC is expected to accumulate drug concentrations in the local liver and reduce systemic toxicity of anti-cancer drugs, it is considered to have a more favorable antitumor effect and less influence on other organs than systemic chemotherapy.  The clinical benefits of HAIC are as follows: (1) even a patient with Child–Pugh B HCC (7 or 8 points) is a candidate for HAIC (2) Child–Pugh scores barely decline with the use of HAIC compared with sorafenib (3) HAIC is highly effective in patients with vascular invasion compared with sorafenib; and (4) survival in patients receiving HAIC may not be associated with skeletal muscle volume. In contrast, the disadvantages are problems related with the reservoir system. HAIC has clinical benefits in a subpopulation of patients without extrahepatic metastasis with Child–Pugh A HCC and vascular invasion (especially primary branch invasion or main portal vein invasion) or with Child–Pugh B HCC.

advanced hepatocellular carcinoma hepatic arterial infusion chemotherapy sorafenib vascular invasion

1. Introduction

The introduction of sorafenib, a molecular-targeted agent (MTA), in 2007, has been a landmark in the history of systemic therapy for advanced hepatocellular carcinoma (HCC). After the success of the SHARP and Asia-Pacific trials [1][2], several clinical trials of new MTAs (e.g., sunitinib, brivanib, and linifanib, among others) conducted from 2007 until 2016 have failed [3][4]. However, the recent success of treatments in clinical trials, such as regorafenib, lenvatinib, cabozantinib, and ramucirumab, has changed the treatment strategy for advanced HCC [5][6][7][8]. Furthermore, the combination of atezolizumab with bevacizumab improved overall and progression-free survival outcomes compared with sorafenib in patients with advanced HCC [9]. This combination therapy was approved for unresectable HCC in clinical practice in the United States (US) and Japan in May 2020 and September 2020, respectively. Therefore, combination therapy is likely considered the first-line therapy for advanced HCC, and current first-line MTAs (sorafenib and lenvatinib) and second-line MTAs (regorafenib, ramucirumab, and cabozantinib) are likely to be shifted to second- and third-line therapies, respectively [10]. However, as these above-mentioned drugs have been recommended to HCC patients with preserved liver, those with deteriorated liver function are generally not candidates for such drugs.

In contrast, hepatic arterial infusion chemotherapy (HAIC), which has been performed since the 1990s in Japan, may be a candidate for addressing an unmet medical need. Although several studies showed the efficacy of HAIC in a subpopulation of patients with advanced HCC [11][12][13][14][15][16][17], various guidelines from Asia, Europe, and the US do not recommend HAIC as a treatment option for advanced HCC due to low evidence levels, except for the Japanese guideline [18][19][20][21]. In addition, technical difficulties and medical care are needed to institute and maintain the reservoir system. Therefore, although HAIC has been used in East Asia, especially Japan, it has low feasibility as a treatment. Sorafenib has been widely used as a standard systemic therapeutic agent for more than 10 years, whereas adoption of HAIC has been limited. In this review, we discuss the current status and clinical benefits of HAIC for advanced HCC compared with sorafenib, based on articles published between 2008 and 2020.

2. Overview of HAIC

2.1. Concept

HAIC involves two procedures as follows: as scheduled, chemotherapeutic regimens are administered through a reservoir port connected to a catheter, which is implanted under the skin, and a catheter is inserted each time without implantation of the reservoir port. As HAIC is expected to accumulate drug concentrations in the local liver and reduce systemic toxicity of anti-cancer drugs, it is considered to have a more favorable antitumor effect and less influence on other organs than systemic chemotherapy. However, currently, no randomized controlled trials (RCTs) have compared HAIC with systemic chemotherapy in a large number of HCC patients.

2.2. Regimens

As the anti-cancer drugs that can be used in HAIC differ across countries, it may be difficult to adopt these HAIC regimens. In Japan, three regimens have been used for HAIC treatment: 5-fluorouracil (5-FU) combined with low-dose cisplatin (CDDP) (low-dose FP) [22][23][24], 5-FU combined with interferon (FAIT) [25][26][27][28], and CDDP alone [29][30][31] (Table 1). The response rates (complete response [CR] + partial response [PR]/all patients) of the regimens comprising low-dose FP or FAIT and the CDDP regimen were approximately 30–40% and 20–30%, respectively. Recently, HAIC regimens comprising low-dose FP or CDDP alone have been generally used in Japan [32].

Table 1. Regimens of hepatic arterial infusion chemotherapy.

Authors [Reference] Publishing Year Regimens Case Number Vascular Invasion (%) Response Rate (%) Median Survival Time (Months)
Low-dose FP
Saeki, et al. [22] 2015 Low-dose FP
including the combination of LV/IV or IV plus IFN		 90 ND 34.4 10.6
Nouso, et al. [23] 2013 CDDP+5FU 476 44.1 40.5 14.0
(341 patients)
Ueshima, et al. [24] 2010 Low-dose FP 52 80.8 38.5 15.9
FAIT
Monden, et al. [25] 2012 IFNα, 5-FU 34 90.0 26.7 8.4
Low-dose FP/CDDP 35 90.3 25.8 11.8
Yamashita, et al. [26] 2011 IFNα, CDDP, 5-FU 57 26.7 45.6 17.6
IFNα, 5-FU 57 50.0 24.6 10.5
Nagano, et al. [27] 2011 IFNα, 5-FU 102 100.0 39.2 9.0
Obi, et al. [28] 2006 IFNα, 5-FU 116 100.0 52.0 6.9
CDDP
Ikeda, et al. [29] 2013 CDDP powder (IA call) 25 100.0 28.0 7.6
Kim, et al. [30] 2011 CDDP 41 83.3 12.2 7.5
CDDP, 5-FU 97 27.8 12.0
Yoshikawa, et al. [31] 2008 CDDP powder (IA call) 80 27.5 33.8 ND

ND, not described; Low-dose FP, low-dose 5-fluorouracil plus cisplatin; LV, leucovorin; IV, isovorin; IFN, interferon; CDDP, cisplatin; 5-FU, 5-fluorouracil.

2.3. Indications

HAIC is commonly used to treat advanced HCC, whether naive or recurrent tumors. According to the Clinical Practice Guidelines for Hepatocellular Carcinoma (2017 version) established by the Japan Society of Hepatology (JSH) [21], HAIC or MTA is recommended as a second-line treatment in HCC patients with ≥4 nodules, without vascular invasion and extrahepatic metastasis (EHM); whereas transcatheter arterial chemoembolization (TACE), hepatectomy, HAIC, and MTA are recommended as first-line treatments in HCC patients with vascular invasion, without EHM. Furthermore, patients with Child–Pugh A or B HCC are candidates for HAIC [21]. In this regard, the guidelines from Korea and Taiwan demonstrated that HAIC may be considered an optional treatment in a subpopulation of patients [33][34].

2.4. Clinical Outcomes

As shown in Table 1, the median survival time (MST) was different based on the degree of vascular invasion. Radiological responders (CR or PR) show significantly longer survival than radiological non-responders (stable or progressive disease). A Japanese nationwide survey reported that the MST was significantly longer in patients who received HAIC (n = 341, 14 months) than in those who did not receive active treatment (n = 341, 5.2 months) in a propensity score-matched analysis [23]. In Child–Pugh A or B HCC patients with portal vein tumor thrombus, the MST was similarly significantly longer in patients receiving HAIC (7.9 months) than in those without therapy (3.1 months) [23]. A recent report demonstrated that none of the HAIC regimens (low-dose FP, FAIT, and CDDP alone) had no effect on survival in patients with advanced HCC [11].

3. Clinical Benefits and Disadvantages of HAIC

The clinical benefits of HAIC for advanced HCC are as follows: (1) even a patient with Child–Pugh B HCC (7 or 8 points) is a candidate for HAIC [35], (2) Child–Pugh scores barely decline after HAIC [36][37], (3) HAIC is highly effective in patients with vascular invasion compared with sorafenib [11][38], and 4) survival in patients receiving HAIC may not be associated with skeletal muscle volume [39]. In contrast, the disadvantages of HAIC for advanced HCC are as follows: (1) a highly technical procedure is needed to implant a catheter with a reservoir port; (2) hospitalization is needed to continue HAIC treatments; (3) patients have to return for follow-up visits every 2 weeks to maintain the reservoir system; and (4) adverse events related to the reservoir system, such as port migration, catheter dislocation, arterial occlusion, reservoir system occlusion, subcutaneous hematomas, or infection [40].

Atezolizumab combined with bevacizumab was recently approved, and this combination will be recommended as the first-line therapy for advanced HCC. However, a comparison between atezolizumab plus bevacizumab and HAIC has not been performed. Patients with macrovascular invasion, including an invasion of the main portal trunk, accounted for 38% of those in the atezolizumab plus bevacizumab group; however, the details were not shown [9]. Therefore, as there has been no information regarding this combination therapy in real-world practice, further studies are required.

We present a draft of the treatment proposal for HAIC for advanced HCC in Figure 1. The combination of atezolizumab and bevacizumab will be shifted to the first-line therapy in patients with Child–Pugh A HCC, regardless of EHM, and currently used MTAs will be shifted to later lines of therapy [10]. HAIC may be an optional treatment in patients with Child–Pugh A HCC and vascular invasion, especially Vp3 or Vp4, without EHM [11][38]. MTAs are generally used in patients with Child–Pugh A HCC, whereas the use of MTAs in patients with Child–Pugh B HCC remains controversial. Some Asian guidelines recommended that sorafenib is considered in selected patients with Child–Pugh B (e.g., score, 7 points) [18][33][34][41][42], although sorafenib treatment significantly worsened survival in patients with Child–Pugh B HCC compared to those with Child–Pugh A HCC [43]. In contrast, patients with Child–Pugh B HCC (score 7 or 8 points) are candidates for HAIC [35]. The medical needs of patients receiving second-line therapy for Child–Pugh B HCC without EHM and those who have EHM with Child–Pugh B HCC, are yet to be met. However, HAIC may be considered in a subpopulation of both Child–Pugh B HCC and EHM patients if the intrahepatic tumor is directly linked to prognosis. Therefore, patients in clinical trials who can tolerate deteriorated liver function would be candidates for the novel therapy [44][45]. We have reported the efficacy of arterial infusion of an iron chelator, deferoxamine, which is not an anti-cancer drug but is used for treating iron overload disease in advanced HCC patients, including Child–Pugh B or C patients [44]. However, deferasirox, an oral iron chelator, has limited efficacy due to associated adverse effects, especially renal dysfunction [45]. In the future, systemic therapeutic agents would be expected to be developed for the unmet medical needs of patients undergoing advanced HCC treatment.

Applsci 11 01882 g001 550

Figure 1. A draft of the treatment proposal for advanced HCC. HCC, hepatocellular carcinoma; HAIC, hepatic arterial infusion chemotherapy; Vp3, primary branch portal vein invasion; Vp4, main portal vein invasion.

References

  1. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390.
  2. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10, 25–34.
  3. Kudo, M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers 2018, 10, 412.
  4. Dong, Y.; Liu, T.H.; Yau, T.; Hsu, C. Novel systemic therapy for hepatocellular carcinoma. Hepatol. Int. 2020, 14, 638–651.
  5. Bruix, J.; Qin, S.; Merle, P.; Granito, A.; Huang, Y.H.; Bodoky, G.; Pracht, M.; Yokosuka, O.; Rosmorduc, O.; Breder, V.; et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017, 389, 56–66.
  6. Kudo, M.; Finn, R.S.; Qin, S.; Han, K.H.; Ikeda, K.; Piscaglia, F.; Baron, A.; Park, J.W.; Han, G.; Jassem, J.; et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018.
  7. Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018, 379, 54–63.
  8. Zhu, A.X.; Kang, Y.K.; Yen, C.J.; Finn, R.S.; Galle, P.R.; Llovet, J.M.; Assenat, E.; Brandi, G.; Pracht, M.; Lim, H.Y.; et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 282–296.
  9. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905.
  10. Kudo, M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020, 9, 367–377.
  11. Ueshima, K.; Ogasawara, S.; Ikeda, M.; Yasui, Y.; Terashima, T.; Yamashita, T.; Obi, S.; Sato, S.; Aikata, H.; Ohmura, T.; et al. Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2020, 9, 583–595.
  12. Choi, J.H.; Chung, W.J.; Bae, S.H.; Song, D.S.; Song, M.J.; Kim, Y.S.; Yim, H.J.; Jung, Y.K.; Suh, S.J.; Park, J.Y.; et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother. Pharmacol. 2018, 82, 469–478.
  13. Kang, M.K.; Park, J.G.; Lee, H.J. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine 2018, 97, e0611.
  14. Moriguchi, M.; Aramaki, T.; Nishiofuku, H.; Sato, R.; Asakura, K.; Yamaguchi, K.; Tanaka, T.; Endo, M.; Itoh, Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017, 6, 275–286.
  15. Song, D.S.; Song, M.J.; Bae, S.H.; Chung, W.J.; Jang, J.Y.; Kim, Y.S.; Lee, S.H.; Park, J.Y.; Yim, H.J.; Cho, S.B.; et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J. Gastroenterol. 2015, 50, 445–454.
  16. Kawaoka, T.; Aikata, H.; Hyogo, H.; Morio, R.; Morio, K.; Hatooka, M.; Fukuhara, T.; Kobayashi, T.; Naeshiro, N.; Miyaki, D.; et al. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J. Dig. Dis. 2015, 16, 505–512.
  17. Fukubayashi, K.; Tanaka, M.; Izumi, K.; Watanabe, T.; Fujie, S.; Kawasaki, T.; Yoshimaru, Y.; Tateyama, M.; Setoyama, H.; Naoe, H.; et al. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparative study using the propensity score matching method. Cancer Med. 2015, 4, 1214–1223.
  18. Omata, M.; Cheng, A.L.; Kokudo, N.; Kudo, M.; Lee, J.M.; Jia, J.; Tateishi, R.; Han, K.H.; Chawla, Y.K.; Shiina, S.; et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol. Int. 2017, 11, 317–370.
  19. European Association for the Study of the Liver. Electric address: Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018.
  20. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750.
  21. Kokudo, N.; Takemura, N.; Hasegawa, K.; Takayama, T.; Kubo, S.; Shimada, M.; Nagano, H.; Hatano, E.; Izumi, N.; Kaneko, S.; et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol. Res. 2019, 49, 1109–1113.
  22. Saeki, I.; Yamasaki, T.; Tanabe, N.; Iwamoto, T.; Matsumoto, T.; Urata, Y.; Hidaka, I.; Ishikawa, T.; Takami, T.; Yamamoto, N.; et al. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS ONE 2015, 10, e0126649.
  23. Nouso, K.; Miyahara, K.; Uchida, D.; Kuwaki, K.; Izumi, N.; Omata, M.; Ichida, T.; Kudo, M.; Ku, Y.; Kokudo, N.; et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br. J. Cancer 2013, 109, 1904–1907.
  24. Ueshima, K.; Kudo, M.; Takita, M.; Nagai, T.; Tatsumi, C.; Ueda, T.; Kitai, S.; Ishikawa, E.; Yada, N.; Inoue, T.; et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010, 78, 148–153.
  25. Monden, M.; Sakon, M.; Sakata, Y.; Ueda, Y.; Hashimura, E. FAIT Research Group. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol. Res. 2012, 42, 150–165.
  26. Yamashita, T.; Arai, K.; Sunagozaka, H.; Ueda, T.; Terashima, T.; Mizukoshi, E.; Sakai, A.; Nakamoto, Y.; Honda, M.; Kaneko, S. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011, 81, 281–290.
  27. Nagano, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Eguchi, H.; Tanemura, M.; Tomimaru, Y.; Osuga, K.; Umeshita, K.; Doki, Y.; et al. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011, 80, 63–69.
  28. Obi, S.; Yoshida, H.; Toune, R.; Unuma, T.; Kanda, M.; Sato, S.; Tateishi, R.; Teratani, T.; Shiina, S.; Omata, M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106, 1990–1997.
  29. Ikeda, M.; Okusaka, T.; Furuse, J.; Mitsunaga, S.; Ueno, H.; Yamaura, H.; Inaba, Y.; Takeuchi, Y.; Satake, M.; Arai, Y. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother. Pharmacol. 2013, 72, 463–470.
  30. Kim, B.K.; Park, J.Y.; Choi, H.J.; Kim, d.Y.; Ahn, S.H.; Kim, J.K.; Lee, D.Y.; Lee, K.H.; Han, K.H. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2011, 137, 659–667.
  31. Yoshikawa, M.; Ono, N.; Yodono, H.; Ichida, T.; Nakamura, H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol. Res. 2008, 38, 474–483.
  32. Kudo, M.; Izumi, N.; Kokudo, N.; Sakamoto, M.; Shiina, S.; Takayama, T.; Tateishi, R.; Nakashima, O.; Murakami, T.; Matsuyama, Y.; et al. Report of the 21th Nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol. Res. 2020.
  33. Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019, 13, 227–299.
  34. Surveillance Group; Diagnosis Group; Staging Group; Surgery Group; Local Ablation Group; TACE/TARE/HAI Group; Target Therapy/Systemic Therapy Group; Radiotherapy Group; Prevention Group; Drafting Group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J. Formos. Med. Assoc. 2018, 117, 381–403.
  35. Terashima, T.; Yamashita, T.; Arai, K.; Kawaguchi, K.; Kitamura, K.; Yamashita, T.; Sakai, Y.; Mizukoshi, E.; Honda, M.; Kaneko, S. Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. Cancer Sci. 2016, 107, 1263–1269.
  36. Terashima, T.; Yamashita, T.; Arai, K.; Kawaguchi, K.; Kitamura, K.; Yamashita, T.; Sakai, Y.; Mizukoshi, E.; Honda, M.; Kaneko, S. Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer 2017, 6, 236–249.
  37. Saeki, I.; Yamasaki, T.; Maeda, M.; Hisanaga, T.; Iwamoto, T.; Matsumoto, T.; Hidaka, I.; Ishikawa, T.; Takami, T.; Sakaida, I. Evaluation of the “assessment for continuous treatment with hepatic arterial infusion chemotherapy” scoring system in patients with advanced hepatocellular carcinoma. Hepatol. Res. 2018, 48, E87–E97.
  38. Liu, M.; Shi, J.; Mou, T.; Wang, Y.; Wu, Z.; Shen, A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J. Gastroenterol. Hepatol. 2020, 35, 1277–1287.
  39. Saeki, I.; Yamasaki, T.; Maeda, M.; Hisanaga, T.; Iwamoto, T.; Matsumoto, T.; Hidaka, I.; Ishikawa, T.; Takami, T.; Sakaida, I. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. PLoS ONE 2019, 14, e0218136.
  40. Obi, S.; Sato, S.; Kawai, T. Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer 2015, 4, 188–199.
  41. Shao, Y.Y.; Wang, S.Y.; Lin, S.M.; Diagnosis Group; Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J. Formos. Med. Assoc. 2020.
  42. Zhou, J.; Sun, H.C.; Wang, Z.; Cong, W.M.; Wang, J.H.; Zeng, M.S.; Yang, J.M.; Bie, P.; Liu, L.X.; Wen, T.F.; et al. Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer 2018, 7, 235–260.
  43. Hollebecque, A.; Cattan, S.; Romano, O.; Sergent, G.; Mourad, A.; Louvet, A.; Dharancy, S.; Boleslawski, E.; Truant, S.; Pruvot, F.R.; et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. Aliment. Pharmacol. Ther. 2011, 34, 1193–1201.
  44. Yamasaki, T.; Terai, S.; Sakaida, I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med. 2011, 365, 576–578.
  45. Saeki, I.; Yamamoto, N.; Yamasaki, T.; Takami, T.; Maeda, M.; Fujisawa, K.; Iwamoto, T.; Matsumoto, T.; Hidaka, I.; Ishikawa, T.; et al. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J. Gastroenterol. 2016, 22, 8967–8977.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Takahiro Yamasaki
View Times: 1.1K
Revisions: 3 times (View History)
Update Date: 12 Oct 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback